Q. Perkins Adelene's most recent trade in Bruker Corp was a trade of 3,298 Common Stock done . Disclosure was reported to the exchange on Feb. 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bruker Corp | Adelene Q. Perkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 3,298 | 24,624 (0%) | 0% | 0 | Common Stock | |
| Bruker Corp | Q. Perkins Adelene | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 2,377 | 21,326 (0%) | 0% | 0 | Common Stock | |
| Bruker Corp | Adelene Q. Perkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 1,970 | 18,949 (0%) | 0% | 0 | Common Stock | |
| Infinity Pharmaceuticals Inc. | Adelene Q. Perkins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2022 | 576,100 | 576,100 | - | - | Stock Option (right to buy) | |
| Bruker Corp | Adelene Q. Perkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 1,841 | 16,979 (0%) | 0% | 0 | Common Stock | |
| Bruker Corp | Adelene Q. Perkins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2021 | 2,302 | 15,138 (0%) | 0% | 0 | Common Stock | |
| Infinity Pharmaceuticals Inc. | Adelene Q. Perkins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2020 | 485,000 | 485,000 | - | - | Stock Option (right to buy) |